Cann Group (ASX:CAN) - Prezzo delle azioni, notizie e analisi

La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

CAN Panoramica delle azioni

Cann Group Limited si occupa di allevamento, coltivazione, produzione, fabbricazione, fornitura e vendita di cannabis terapeutica.

Informazioni sull'azienda

CAN analisi fondamentale
Punteggio fiocco di neve
Valutazione	2/6
Crescita futura	0/6
Prestazioni passate	0/6
Salute finanziaria	1/6
Dividendi	0/6

Premi

Analisi del rischio

Ha meno di 1 anno di pista di cassa

Gli utili sono diminuiti del 24.3% all'anno negli ultimi 5 anni

Non ha una capitalizzazione di mercato significativa ( A$15M )

Gli azionisti sono stati diluiti nell'ultimo anno

Cann Group Limited Concorrenti

AusCann Group Holdings

ASX:AC8

AU$17.6m

Althea Group Holdings

ASX:AGH

AU$10.2m

Rhinomed

ASX:RNO

AU$11.5m

Little Green Pharma

ASX:LGP

AU$29.6m

Storia dei prezzi e prestazioni

Riepilogo dei massimi storici, delle variazioni e dei cali di prezzo di tutti i tempi per Cann Group
Prezzi storici delle azioni
Prezzo attuale dell'azione	AU$0.034
Massimo di 52 settimane	AU$0.19
Minimo di 52 settimane	AU$0.027
Beta	1.08
1Variazione di 1 mese	17.24%
Variazione a 3 mesi	n/a
Variazione di 1 anno	-72.80%
3Variazione a 3 anni	-88.28%
Variazione a 5 anni	-98.20%
Variazione dall'IPO	-94.73%

Notizie e aggiornamenti recenti

Cann Group Limited's (ASX:CAN) Low P/S No Reason For Excitement

Jun 04

Recent updates

Shareholders May Be A Bit More Conservative With Cann Group Limited's (ASX:CAN) CEO Compensation For Now

Nov 03

Here's Why We're Not Too Worried About Cann Group's (ASX:CAN) Cash Burn Situation

Feb 23

What Type Of Returns Would Cann Group's(ASX:CAN) Shareholders Have Earned If They Purchased Their SharesThree Years Ago?

Nov 25

One Forecaster Is Now More Bearish On Cann Group Limited (ASX:CAN) Than They Used To Be

Nov 25

Rendimenti per gli azionisti

	CAN	AU Pharmaceuticals	AU Mercato
7D	3.0%	0.9%	2.2%
1Y	-72.8%	52.4%	11.2%

Ritorno vs Industria: CAN ha avuto una performance inferiore rispetto al Australian Pharmaceuticals che ha registrato un rendimento 52.4 % nell'ultimo anno.

Rendimento vs Mercato: CAN ha avuto una performance inferiore al mercato Australian che ha registrato un rendimento 11.2 % nell'ultimo anno.

Volatilità dei prezzi

Is CAN's price volatile compared to industry and market?
CAN volatility
CAN Average Weekly Movement	12.2%
Pharmaceuticals Industry Average Movement	10.1%
Market Average Movement	8.2%
10% most volatile stocks in AU Market	16.9%
10% least volatile stocks in AU Market	3.4%

Prezzo delle azioni stabile: Il prezzo delle azioni di CAN è stato volatile negli ultimi 3 mesi.

Volatilità nel tempo: La volatilità settimanale ( 12% ) di CAN è rimasta stabile nell'ultimo anno.

Informazioni sull'azienda

Fondato	I dipendenti	AMMINISTRATORE DELEGATO	Sito web
2014	n/a	Jenni Pilcher	www.canngrouplimited.com

Cann Group Limited si occupa di allevamento, coltivazione, produzione, fabbricazione, fornitura e vendita di cannabis terapeutica. Ha licenze per intraprendere ricerche e coltivare cannabis per scopi terapeutici e di ricerca. La società è stata fondata nel 2014 e ha sede a Port Melbourne, in Australia.

Cann Group Limited Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di Cann Group con la sua capitalizzazione di mercato?
CAN statistiche fondamentali
Capitalizzazione di mercato	AU$15.42m
Guadagni(TTM)	-AU$29.28m
Ricavi(TTM)	AU$21.34m

0.7x

Rapporto P/S

-0.5x

Rapporto P/E

CAN è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Guadagni e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
CAN Conto economico (TTM)
Ricavi	AU$21.34m
Costo del fatturato	-AU$955.00k
Profitto lordo	AU$22.29m
Altre spese	AU$51.58m
Guadagni	-AU$29.28m

Ultimi guadagni dichiarati

Dec 31, 2023

Prossima data di guadagno

Aug 30, 2024

Utile per azione (EPS)	-0.063
Margine lordo	104.48%
Margine di profitto netto	-137.24%
Rapporto debito/patrimonio netto	129.2%

Come si è comportato CAN nel lungo periodo?

Vedi performance storica e confronto

CAN Panoramica delle azioni

Premi

Analisi del rischio

Cann Group Limited Concorrenti

ASX:AC8

AU$17.6m

ASX:AGH

AU$10.2m

ASX:RNO

AU$11.5m

ASX:LGP

AU$29.6m

Storia dei prezzi e prestazioni

Notizie e aggiornamenti recenti

Cann Group Limited to Report Fiscal Year 2024 Results on Aug 30, 2024

Cann Group Limited Appoints Jenni Pilcher as Managing Director

Less than half of directors are independent

Cann Group Limited's (ASX:CAN) Low P/S No Reason For Excitement

New major risk - Financial position

Cann Group Limited Appoints Tony Di Pietro as Joint Company Secretary of Head of Legal and Regulatory Affairs

Recent updates

Cann Group Limited to Report Fiscal Year 2024 Results on Aug 30, 2024

Cann Group Limited Appoints Jenni Pilcher as Managing Director

Less than half of directors are independent

Cann Group Limited's (ASX:CAN) Low P/S No Reason For Excitement

New major risk - Financial position

Cann Group Limited Appoints Tony Di Pietro as Joint Company Secretary of Head of Legal and Regulatory Affairs

A Piece Of The Puzzle Missing From Cann Group Limited's (ASX:CAN) Share Price

Cann Group Limited Announces Resignation of Deborah Ambrosini as Chief Financial Officer, Effective December 22, 2023

Cann Group Limited has filed a Follow-on Equity Offering in the amount of AUD 0.3756 million.

Cann Group Limited, Annual General Meeting, Oct 26, 2023

Full year 2023 earnings released: AU$0.091 loss per share (vs AU$0.079 loss in FY 2022)

New minor risk - Financial data availability

Cann Group Limited has completed a Follow-on Equity Offering in the amount of AUD 11.658446 million.

Cann Group Limited Provides Revenue Guidance for the Year Ended June 30, 2023

Cann Group (ASX:CAN) Is Making Moderate Use Of Debt

First half 2023 earnings released: AU$0.053 loss per share (vs AU$0.028 loss in 1H 2022)

Cann Group Limited Announces Preliminary Results from Their Phase 3 Clinical Trail

Cann Group Limited Announces Chief Executive Officer Changes

Cann Group Limited Announces Final Clinical Trial Participant Completes Study

Less than half of directors are independent

Cann Group Limited Appoints Julian John Chick as Director

Cann Group Limited Announces Resignation of Peter Crock as CEO

Cann Group Limited Meets its Enrolment Target for Phase III Clinical Trial of Low-Dose Satipharm CBD Capsules for Short-Term Sleep Disturbance

Cann Group Limited Announces Executive Changes

Cann Group Limited Appoints Robert Barnes & Julian Chick to the Board

Cann Group Limited Announces Resignation of John Sharman as Director

Cann Group Limited, Annual General Meeting, Oct 25, 2022

Full year 2022 earnings released: AU$0.079 loss per share (vs AU$0.098 loss in FY 2021)

Cann Group Limited Announce Therapeutic Goods Administration Grants Cann GMP License to Manufacture Therapeutic Goods

Cann Group Limited Receives Second Payment from Victorian Government's Regional Jobs Fund Program

Less than half of directors are independent

Office of Drug Control Grants Permit for Manufacture of Medicinal Cannabis Products to Cann Group Limited

First half 2022 earnings: Revenues and EPS in line with analyst expectations

Cann Group Limited Announces Resignation of Mr. Geoffrey Pearce as Non-Executive Director

Cann Group Limited Announces Cann to Begin Recruitment for CBD Phase 3 Clinical Trial

Rua Bioscience Limited (NZSE:RUA) agreed to acquire 8.36% stake in Zalm Therapeutics Ltd from Cann Group Limited (ASX:CAN) for NZD 10 million.

Shareholders May Be A Bit More Conservative With Cann Group Limited's (ASX:CAN) CEO Compensation For Now

Chief Financial Officer Greg Bullock has left the company

Full year 2021 earnings released: AU$0.097 loss per share (vs AU$0.12 loss in FY 2020)

Cann Group Limited Revises Revenue Guidance for the Year 2021

Cann Group Limited (ASX:CAN) completed the acquisition of Satipharm Ltd, Satipharm AG and Phytotech Therapeutics Ltd from Harvest One Cannabis Inc. (TSXV:HVT)

Cann Group Limited, Olivia Newton-John Cancer Research Institute and Austin Health Partnered in A Clinical Tria to Assess Medicinal Cannabis for Symptom Management in People with Advanced Cancer

Cann Group Limited (ASX:CAN) entered into a definitive sale agreement to acquire Phytotech Therapeutics Ltd from Harvest One Cannabis Inc. (TSXV:HVT).

First half 2021 earnings released: AU$0.05 loss per share (vs AU$0.06 loss in 1H 2020)

Here's Why We're Not Too Worried About Cann Group's (ASX:CAN) Cash Burn Situation

Cann Group Limited (ASX:CAN) signed a share sale agreement to acquire Satipharm Ltd from Harvest One Cannabis Inc. (TSXV:HVT) for CAD 4 million.

New 90-day high: AU$0.78

Australis Capital Inc. and Cann Group Limited Sign Agreement

Price target lowered to AU$1.12

Cann Group Limited Receives Initial 19,000 Unit Order for Europe

What Type Of Returns Would Cann Group's(ASX:CAN) Shareholders Have Earned If They Purchased Their SharesThree Years Ago?

One Forecaster Is Now More Bearish On Cann Group Limited (ASX:CAN) Than They Used To Be

Analysts update estimates

New 90-day high: AU$0.51

Deputy Chairman recently bought AU$55k worth of stock

An unknown buyers acquired 11.84% stake in Cann Group Limited (ASX:CAN) from Aurora Cannabis Inc. (TSX:ACB).

New 90-day low: AU$0.38

Cann Group Limited(ASX:CAN) dropped from S&P Global BMI Index

Deputy Chairman recently bought AU$79k worth of stock